State Of Wyoming Prothena Corp Public LTD CO Transaction History

State Of Wyoming

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$22.73 - $39.98 $113,218 - $199,140	-4,981 Reduced 83.76%	966 $26,000
Q1 2022 May 13, 2022	BUY	$30.27 - $49.22 $21,491 - $34,946	710 Added 13.56%	5,947 $218,000
Q4 2021 Feb 11, 2022	BUY	$42.11 - $73.26 $21,139 - $36,776	502 Added 10.6%	5,237 $259,000
Q3 2021 Feb 11, 2022	SELL	$48.2 - $78.89 $24,726 - $40,470	-513 Reduced 9.78%	4,735 $337,000
Q2 2021 Feb 11, 2022	BUY	$21.63 - $57.65 $113,514 - $302,547	5,248 New	5,248 $270,000

185

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $668M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.